Flurpiridaz F-18 PET/CT Imaging for Detecting Parathyroid Adenomas
Flurpiridaz F-18 PET/CT Imaging for Detecting Parathyroid Adenomas in Patients With Primary Hyperparathyroidism
Study of Flurpiridaz F-18 positron emission tomography/computed tomography (PET/CT) as a diagnostic imaging tool to detect abnormal parathyroid glands in patients with primary hyperparathyroidism, prior to multi-parathyroid gland surgical exploration. Patients with known or suspected parathyroid adenomas will be eligible for this study. Comparisons of diagnostic performance using Flurpiridaz F-18 PET/CT versus standard of care dual time point sestamibi single photon emission computed computed tomography/computed tomography (SPECT/CT) imaging will be tested.
研究概览
详细说明
Patients with known or suspected parathyroid adenomas will be eligible for this study. Comparisons of diagnostic performance using Flurpiridaz F-18 (fluorine-18) PET/CT versus standard of care dual time point sestamibi SPECT/CT imaging will be tested.
研究类型
注册 (估计的)
阶段
- 第一阶段早期
联系人和位置
学习联系方式
- 姓名:Erin Schubert, BA
- 电话号码:215-573-6569
- 邮箱:erin.schubert@pennmedicine.upenn.edu
研究联系人备份
- 姓名:Mary Hansbury, BS
- 电话号码:215-746-8192
- 邮箱:mary.hansbury@pennmedicine.upenn.edu
学习地点
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- 招聘中
- Unversity of Pennsylvania
-
接触:
- Erin Schubert, BA
- 电话号码:215-573-6569
- 邮箱:erin.schubert@pennmedicine.upenn.edu
-
接触:
- Mary Hansbury, BS
- 电话号码:215-746-8192
- 邮箱:mary.hansbury@pennmedicine.upenn.edu
-
首席研究员:
- Victor Babatunde, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Adult patients, at least 18 years of age
- History of primary hyperparathyroidism as clinically confirmed by serum laboratory values of elevated calcium levels (>10.2 mg/dl) and abnormal or inappropriately normal parathyroid hormone concentrations (normal range: 15 to 65 pg/ml).
- Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.
- Participants must have had prior SPECT/CT sestamibi parathyroid imaging within 6 months of this investigational study or planned SPECT/CT sestamibi parathyroid imaging scheduled prior to this investigational study.
- Planned surgery within 6 months following this investigational study.
Exclusion Criteria:
- Females who are pregnant or breast feeding at the time of the PET/CT scan will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential ( as self-reported by menstrual history) before the injection of radiotracer.
- Inability to tolerate imaging procedures, including but not limited to claustrophobia, inability to remain still during scanning, or any other condition that, in the judgment of the investigator or treating physician, would interfere with safe or adequate imaging.
- Serious or unstable medical or psychological conditions that, in the opinion of the investigator would compromise the subject's safety or successful participation in the study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:诊断
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Flycardo PET/CT
Flycardo PET/CT scan in patients with primary hyperparathyroidism |
Flurpiridaz is a FDA approved radiopharmaceutical used with PET/CT imaging |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Sensitivity
大体时间:4 weeks
|
Qualitative positive or negative PET/CT |
4 weeks
|
|
sensitivity
大体时间:6 weeks
|
comparison of specificity of PET/CT imaging with standard dual-energy Sestamibi imaging |
6 weeks
|
合作者和调查者
调查人员
- 首席研究员:Victor Babatunde, MD、University of Pennsylvania
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.